ROCKVILLE, Md., Aug. 14, 2018 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced the closing of its previously announced
underwritten public offering of 2,700,000 shares of its common
stock at a price to the public of $65.00 per share, as well as the exercise in full
of the underwriters' option to purchase 405,000 additional shares
at the public offering price. Including the option exercise, the
total gross proceeds to REGENXBIO are expected to be approximately
$201.8 million, before deducting the
underwriting discounts and commissions and estimated offering
expenses.
Morgan Stanley, BofA Merrill Lynch and Barclays acted as joint
book-running managers. Raymond James
acted as co-manager of the offering.
The securities described above were offered by REGENXBIO
pursuant to a shelf registration statement on Form S-3 that was
filed with the Securities and Exchange Commission (the "SEC") on
August 8, 2018, which became
automatically effective upon filing. A final prospectus supplement
relating to and describing the terms of the offering was filed with
the SEC and is available on the SEC's website at www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from: Morgan
Stanley at Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY, 10014; BofA
Merrill Lynch at NC1-004-03-43, 200 North College Street, 3rd
floor, Charlotte, NC 28255-0001,
Attention: Prospectus Department or by email at
dg.prospectus_requests@baml.com; or Barclays, c/o Broadridge
Financial Solutions, at 1155 Long Island Avenue, Edgewood, New York 11717 or by email at
barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy any of these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the applicable securities
laws of such state or jurisdiction.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "design," "intend,"
"expect," "could," "plan," "potential," "predict," "seek,"
"should," "would" or by variations of such words or by similar
expressions. The forward-looking statements include statements
relating to, among other things, REGENXBIO's offering of its common
stock. REGENXBIO has based these forward-looking statements on its
current expectations and assumptions as well as other factors
REGENXBIO believes are appropriate under the circumstances.
However, whether actual results and developments will conform with
REGENXBIO's expectations and predictions is subject to a number of
risks and uncertainties, many of which are beyond the control of
REGENXBIO. For a discussion of these risks, refer to the "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of REGENXBIO's Annual
Report on Form 10-K for the year ended December 31, 2017 and Quarterly Report on Form
10-Q for the quarter ended June 30,
2018 and other filings with the SEC, which are available on
the SEC's website at www.sec.gov. All of the forward-looking
statements made in this press release are expressly qualified by
the cautionary statements contained or referred to herein. The
actual results or developments anticipated may not be realized or,
even if substantially realized, they may not have the expected
consequences to or effects on REGENXBIO or its businesses or
operations. Such statements are not guarantees of future
performance and actual results or developments may differ
materially from those projected in the forward-looking statements.
Readers are cautioned not to rely too heavily on the
forward-looking statements contained in this press release. These
forward-looking statements speak only as of the date of this press
release. REGENXBIO does not undertake any obligation, and
specifically declines any obligation, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT:
Investors
Natalie Wildenradt,
646-681-8192
natalie@argotpartners.com
Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300696382.html
SOURCE REGENXBIO Inc.